What is sipuleucel-T vaccine?
Sipuleucel-T (Provenge) is a cancer vaccine approved by the US Food and Drug Administration to treat men with hormone-refractory prostate cancer.
What is sipuleucel-T used for?
A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels).
Does sipuleucel-t work?
At 36 months, a survival benefit of 4.1 months was noted with sipuleucel-T; median survival was 25.8 months with sipuleucel-T and 21.7 months with placebo. Overall survival was significantly prolonged for sipuleucel-T patients (P = 0.032; HR = 0.775) at the time of cutoff.
What type of cancer is sipuleucel-T used to treat?
Sipuleucel-T is an autologous cellular vaccine, first-in-class in prostate cancer, used for the treatment of asymptomatic, metastatic, bone-only and castration-resistant prostate cancer.
How effective is sipuleucel?
With a median follow-up of 34.1 months and complete survival follow-up data for 99% of patients, treatment with sipuleucel-T resulted in a 4.1-month improvement in median survival and an improvement in the rate of 3-year survival (31.7% for patients receiving sipuleucel-T, as compared with 23.0% for those receiving …
Is Sipuleucel-T FDA approved?
Introduction. In April 2010, the U.S. Food and Drug Administration (FDA) approved PROVENGE (sipuleucel-T; Dendreon), an autologous cellular immunotherapy, for the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
How effective is Provenge?
One study found that Provenge extended survival in people with mCRPC by about 4 months. For people who received Provenge, there was a 22% lower risk of death compared with people who didn’t receive Provenge.
How does sipuleucel work?
Sipuleucel-t is an autologous immunotherapy that activates a man’s immune cells to multiply and attack prostate cancer cells by way of activating certain immune cells with a vaccine that triggers immune cells to identify prostate cancer cells by an antigen that is highly specific to prostate cancer.
Is sipuleucel-T a passive immunotherapy agent?
Sipuleucel-T is a form of active specific immunotherapy. The sipuleucel-T intervention involves harvesting the patient’s peripheral-blood mononuclear cells (PBMCs), culturing them with a chimeric protein . . .
Does PROVENGE lower PSA?
PROVENGE works differently from other cancer treatments, such as chemotherapy or hormone therapy. Unlike these treatments, PROVENGE may not lower your PSA level. The goal of PROVENGE treatment is not to lower PSA level, it is to extend life.
How is sipuleucel administered?
Sipuleucel-T injection comes as a suspension (liquid) to be injected over about 60 minutes into a vein by a doctor or nurse in a doctor’s office or infusion center. It is usually given once every 2 weeks for a total of three doses.
What is the difference between passive and active immunotherapy?
Immunotherapy. Immunotherapy can be either active or passive. Active immunotherapy involves setting an immune response in the cancer patient to fight cancer cells. In passive immunotherapy, immune molecules are given to patients who do not produce them on their own.
What is an example of a passive immunotherapy agent?
Passive immunotherapy includes the administration of immune system components, such as antibodies, to target foreign body cells like cancer cells. Monoclonal antibodies (mAb’s) still represent the largest class of commercialized cancer immunotherapies and are directed to a single target on a cancer cell.
Is sipuleucel T a passive immunotherapy agent?
How many types of immunotherapy are there?
There are currently five different classes of immunotherapies available for patients, for over 20 cancer types.
What is the difference between active and passive immunotherapy?
Immunotherapy can be either active or passive. Active immunotherapy involves setting an immune response in the cancer patient to fight cancer cells. In passive immunotherapy, immune molecules are given to patients who do not produce them on their own. Both approaches can be specific or nonspecific.
Does Provenge really work?
Clinical studies have shown Provenge to be effective for treating metastatic, castration-resistant prostate cancer in adult males. In one study, adults with prostate cancer were randomly given either Provenge or a placebo (a treatment with no active drug).